Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis | Zendy

Noha N. Salama | Zendy; Jonathan H. Segal | Zendy; Mariann D. Churchwell | Zendy; Jignesh H. Patel | Zendy; Lihong Gao | Zendy; Michael Heung | Zendy; Bruce A. Mueller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis

Author(s) -

Noha N. Salama,

Jonathan H. Segal,

Mariann D. Churchwell,

Jignesh H. Patel,

Lihong Gao,

Michael Heung,

Bruce A. Mueller

Publication year - 2009

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.01650309

Subject(s) - daptomycin , medicine , hemodialysis , pharmacokinetics , end stage renal disease , urology , pharmacodynamics , crossover study , vancomycin , staphylococcus aureus , placebo , alternative medicine , pathology , biology , bacteria , genetics

Infusion of intravenous antibiotics after hemodialysis (HD) may delay initiation of treatment for the next HD shift. Intradialytic administration of drugs such as vancomycin during the final hour of HD obviates these delays. Daptomycin has potent activity against Gram-positive bacteria, but the manufacturer recommends that the dose be infused after HD ends. This study determined the pharmacokinetics of intradialytically dosed daptomycin in patients with ESRD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research